← back to database
T. Rowe Price
HQ · Maryland
Late-stage private investing across private equity and growth, with a record of private-company investments. The firm’s managed accounts participated as a new investor in the Series B financing for Kardigan, a cardiovascular therapeutics company in 2025.
Stage focus
Specialization
Investing team
- Emma NorchetPartner, Private Opportunities Fund investment committee; Centralized Private Equity team
- David DiPietroHead of Private Equity team; Private Opportunities Fund investment committee
Sources
kardigan.bio/wp-content/uploads/2025/10/Kardigan_Series_B_Financing_Press_Release_101425.pdf ↗troweprice.com/en/us/investment-capabilities/private-markets ↗troweprice.com/en/us/press/2026/press-release--t--rowe-price-goldman-sachs-private-markets-fund- ↗troweprice.com/institutional/au/en/bios/biodetails.bio-emma-norchet.html ↗troweprice.com/corporate/us/en/home.html ↗